Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View

The increased use of newer potent immunomodulatory therapies for multiple sclerosis (MS), including natalizumab, fingolimod, and dimethyl fumarate, has expanded the patient population at risk for developing progressive multifocal leukoencephalopathy (PML). These MS therapies shift the profile of lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Elizabeth A., Mao-Draayer, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801425/
https://www.ncbi.nlm.nih.gov/pubmed/29456537
http://dx.doi.org/10.3389/fimmu.2018.00138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801425/
https://www.ncbi.nlm.nih.gov/pubmed/29456537
http://dx.doi.org/10.3389/fimmu.2018.00138

Ejemplares similares